Global Health World News

The European Union (EU) has approved Swiss pharmaceutical giant Novartis’ new prostate cancer treatment.

The European Union (EU) has approved Novartis’ new advanced cancer treatment, Swiss pharmaceutical company Novartis announced on December 13.

The treatment, called Pluvicto, has been approved for adult patients with metastatic prostate cancer, Novartis said.

In 2022, there were more than 1.4 million new cases of prostate cancer and 375,000 deaths worldwide, the company reported.

Prostate cancer is the most frequently diagnosed cancer in men in 112 countries, the statement added.

Health authorities approved the new therapy in the United States in March, and in the United Kingdom, Canada has also recognized it.

The European Union’s recognition is a major milestone for patients with advanced prostate cancer, where there are few treatment options, said Hassan Ahmed, Novartis’ European president.

The European Commission has approved this therapy for patients who are being treated with two other treatments. Other prostate cancer therapies include androgen receptor pathway inhibition and taxane-based cancer drugs.

This approval is based on a three-stage test. Novartis reported that 831 patients participated in the trial. Their experimental treatment showed a 38 percent reduction in the risk of death compared to current treatments.

Swiss drug giant Novartis is said to be studying the potential of using this treatment to treat early stages of prostate cancer.

More than 90 percent of men with prostate cancer live five years or longer after treatment. Therefore, prostate cancer is the easiest cancer to treat.

Novartis is a global pharmaceutical company based in Switzerland. A company developing treatments.

Vitamin D deficiency It is reported that Novartis is also producing and selling tablets for calcium deficiency.

The new prostate cancer treatment method is radiation treatment. It is a blood injection treatment, the company said in a statement.

Leave a Reply

Your email address will not be published. Required fields are marked *